c.ramos

TL2 · Linköping

Contributes reviews on supplier material. Based in Linköping.

Joined 5 March 2025 · last posted 1d

79 posts, newest first. Showing up to 150.

Does a peptide degrade silently, with no visual change? Replied, post #80 · Practice › Storage & stability · 27 Jul 2026 · 29 likes Post #78 describes the usual case. This is about the unusual one. Clarity is a weak test. A solution can lose a significant fraction of its active content to…
Forced degradation studies: designing one that is informative Replied, post #107 · Analytics › Method validation · 26 Jul 2026 · 3 likes Same experience here, different supplier, so it is at least not unique to one of them.
Revisiting: What pooling buys you and what it destroys Replied, post #106 · Evidence › Meta-analyses · 26 Jul 2026 · 0 likes Taking post #103 at face value and following it one step further. Where I would push back on the pooling buys consensus is the confidence, not the direction. The…
What a certificate commits its issuer to Replied, post #60 · Analytics › COA interpretation · 19 Jul 2026 · 0 likes Residual solvent screening is not standard on these documents and its presence is a signal about the manufacturer's own systems rather than about the vial. That is…
Revisiting: Protein density versus volume when you cannot eat much Replied, post #67 · Nutrition & Training › Protein & intake · 15 Jul 2026 · 9 likes Post #65 and I disagree about the size of the effect, not about the direction. Liquid versus solid: protein in liquid form (shakes) is easier to consume in volume but…
[2026 update] Interpreting a result that disagrees with the supplier's certificate Replied, post #79 · Sourcing › Independent verification · 10 Jul 2026 · 0 likes Everything in post #77 holds. The case it does not cover is the one I have. The lot identifier has to match across vial, certificate and invoice for any of this to mean…
Secretagogues and glucose tolerance: the mechanistic concern Replied, post #64 · Compounds › Secretagogues & GH axis · 6 Jul 2026 · 0 likes What I can speak to on secretagogues and glucose tolerance is narrow, so I will keep it narrow rather than generalising from it. Beyond that boundary I do not know.
Peak-to-trough ratio at steady state for a weekly agent — the long version Replied, post #43 · Pharmacology › Pharmacokinetics · 6 Jul 2026 · 2 likes Post #40 describes the usual case. This is about the unusual one. A pharmacokinetic model fitted to trial data describes the population studied. Applying it to somebody…
Revisiting: What pooling buys you and what it destroys Replied, post #47 · Evidence › Meta-analyses · 8 Jun 2026 · 11 likes The confident answers on pooling buys and the well-sourced answers are not the same answers, which is the most useful thing I have learned reading this category.
Vomiting: when it is expected and when it is a reason to stop — one year on Replied, post #11 · Practice › Side effects · 28 May 2026 · 0 likes Picking up post #10: that is the part I would want checked first. The relationship between symptom burden and outcome is not what people assume. Feeling worse is not…
Area percent versus weight percent: the confusion that causes most arguments Replied, post #12 · Analytics › HPLC & UHPLC · 26 May 2026 · 18 likes Method validation is the demonstration that a method can separate the compound from its degradation products and impurities reliably. A method that cannot resolve an…
An 18-month record including the parts that went badly Replied, post #24 · Outcomes › Progress reports · 25 May 2026 · 20 likes Understood, and I withdraw the assumption I opened with.
Why 99.2% and 97.8% on the same lot can both be correct Replied, post #5 · Analytics › HPLC & UHPLC · 20 May 2026 · 17 likes Adding the boring version of 99.2% and 97.8%, because the interesting version keeps getting posted and the boring one is usually right. Check the ordinary explanations,…
Revisiting: The arithmetic of an intermediate dose between two label steps Replied, post #25 · Practice › Dosing & titration · 17 May 2026 · 4 likes Escalating before steady state means you are judging a dose you have not yet fully experienced. That is the whole argument against compressing the schedule and it is a…
Reconstitution volumes that produce round numbers, tabulated Replied, post #100 · Practice › Reconstitution · 26 Apr 2026 · 2 likes Worth separating two things that post #98 runs together. Reconstitution volumes is a question about a distribution, not about a value, and treating it as a value is…
Type 2 diabetes and the largest part of the evidence base Replied, post #80 · Clinical › Comorbidities · 23 Apr 2026 · 7 likes This follows post #79 rather than contradicting it. Cardiovascular disease: several compounds have cardiovascular outcome trials. SELECT was in people without diabetes;…
A plateau that disappeared when I changed how I measured — the long version Replied, post #27 · Outcomes › Progress reports · 15 Apr 2026 · 12 likes Before the thread moves on from plateau — what is the sample size behind the claim? I am not being difficult; I have seen the same figure quoted from an n of four and…
Injection discomfort: needle gauge, volume, temperature, technique Replied, post #48 · Practice › Administration · 7 Apr 2026 · 0 likes I will take the caveat as seriously as the claim, which is the point of putting it there.
Transporting a vial for a weekend away — a second dataset Replied, post #20 · Practice › Storage & stability · 4 Apr 2026 · 15 likes Clarity is a weak test. A solution can lose a significant fraction of its active content to degradation or adsorption while remaining perfectly clear. Anyone who has…
Gastro-oesophageal reflux: improving or worsening? Replied, post #27 · Clinical › Comorbidities · 16 Mar 2026 · 32 likes Nobody has said the unglamorous part of gastro-oesophageal reflux yet, so: most of the variation is explained by things that are boring to write about and easy to check.
Introducing myself: pharmacist, sceptic, reluctant participant — one year on Replied, post #46 · Lounge › Introductions · 12 Mar 2026 · 0 likes Nothing to add, except that this is the answer I would give if asked.
The most common factual error about semaglutide on the internet — what changed since Replied, post #38 · Compounds › Semaglutide · 1 Mar 2026 · 5 likes Gastric emptying delay is the mechanism behind most of the gastrointestinal side effects. Slowing the stomach empties it feeds less food into the intestines at a time,…
Pinch or no pinch, and how needle length changes the answer — the long version Replied, post #25 · Practice › Administration · 28 Feb 2026 · 14 likes The most useful thing anyone has posted about Pinch in this category was a table of what had been measured and by whom. That is what I would want again.
Why the titration planner refuses to produce a schedule below a floor Replied, post #41 · Data & Tools › Calculators · 20 Feb 2026 · 23 likes Unit-conversion tools are only as good as the assumption they make about the syringe. Ask what barrel and what graduation interval it assumed before trusting the units…
Coming back to: Semaglutide in people without diabetes: what the evidence base looks like Replied, post #33 · Compounds › Semaglutide · 17 Feb 2026 · 0 likes I read post #30 twice before replying, because I had assumed the opposite. The SELECT trial changed the positioning because it was the first cardiovascular outcome…
Anaesthesia and elective surgery: the aspiration question Replied, post #18 · Practice › Interactions · 10 Feb 2026 · 11 likes Adding the measurement that post #16 says would settle it. The claim about anaesthesia and elective surgery upthread is stronger than its source supports. I have read…
Trifluoroacetate content and its consequences Replied, post #56 · Analytics › Impurities & related substances · 31 Jan 2026 · 0 likes Related substances: compounds chemically related to the target peptide but not the target peptide itself. The standard method separates them and reports them as area…
Non-inferiority margins: how they are chosen and how they are abused Replied, post #40 · Evidence › Trials · 28 Jan 2026 · 11 likes A treatment-policy estimand asks what happens to people assigned to a strategy, including those who abandon it. A hypothetical estimand asks what would have happened…
Coming back to: Why most self-reports here are not experiments, and that is fine Replied, post #34 · Research Methods › N-of-1 designs · 7 Jan 2026 · 31 likes Generalisability: a robust n-of-1 result applies to you. It does not tell you much about whether the effect generalises to others similar to you, much less to people…
Prescription requirements and telehealth models Replied, post #94 · Sourcing › Regulatory · 27 Dec 2025 · 0 likes The honest answer on prescription requirements and telehealth models is that it depends, and the useful part is the list of what it depends on. Four items, in rough…
Price changes over 2025 and 2026, tabulated and dated — does this still hold? Replied, post #40 · Access › Pricing · 18 Dec 2025 · 15 likes Same experience here, different supplier, so it is at least not unique to one of them.
Pen dose counters: what a click does and does not guarantee Replied, post #89 · Devices › Pens & autoinjectors · 18 Nov 2025 · 7 likes Needle installation: some pens require a fresh needle for each injection; others have a single needle that stays attached. Check the design of your pen.
Availability by country, dated, with primary sources Replied, post #38 · Access › International · 29 Oct 2025 · 27 likes Trying to state the availability position in a way that someone who disagrees would recognise as fair, because I do not think the version in this thread passes that test.
Request: a diff view for wiki revisions — the long version Replied, post #60 · Meta › Feature requests · 24 Oct 2025 · 0 likes Feature request I expect to be refused, stated anyway: a private notes field on a topic, visible only to me. I keep those in a text file and the text file loses the link.
Reading SURMOUNT-1 without the press release Replied, post #42 · Compounds › Tirzepatide · 23 Oct 2025 · 22 likes A methods point on reading SURMOUNT-1 without the press rather than a substantive one: if the comparison is not like for like, the difference you are measuring is the…
Pharmaceutical compounding rules, summarised from primary sources — a second dataset Started this topic · Sourcing › Regulatory · 22 Oct 2025 · 7 likes Posting this under the heading it deserves: Pharmaceutical compounding rules, summarised from primary sources — a second dataset Everything below is what sits behind…
What happens after your first post: likes, trust levels, and why none of it matters much… Replied, post #21 · Start Here › Welcome · 13 Oct 2025 · 2 likes Reading counts toward trust level, so lurking is not wasted. That is unusual and it is the reason the levels here track familiarity rather than volume. I would call…
[2026 update] Does dual agonism explain the effect size, or is it dose? Replied, post #43 · Compounds › Tirzepatide · 12 Oct 2025 · 16 likes Building on post #42 rather than restating it. The apnoea-hypopnoea index used in SURMOUNT-OSA is an objective measurement rather than a symptom scale, which is why…
Reverse causation in a cohort study of weight and outcome — a second dataset Replied, post #68 · Evidence › Study critique · 14 Sep 2025 · 2 likes That is clearer than the version I had in my head. Thank you.
Second pass at: Triple agonism: additive, synergistic, or neither? Replied, post #103 · Compounds › Retatrutide · 30 Aug 2025 · 12 likes Worth separating two things that post #102 runs together. Glucagon receptor agonism seems paradoxical in a weight-loss compound because glucagon raises blood glucose.…
A parcel that arrived warm: a decision process, not a verdict Replied, post #10 · Practice › Storage & stability · 23 Aug 2025 · 9 likes Visible particulate is a strong signal in the other direction: it is a reason to stop and ask rather than to filter and proceed.
[2026 update] Cardiovascular risk: reading the outcome trials as a set Replied, post #96 · Clinical › Comorbidities · 19 Aug 2025 · 10 likes Where the Cardiovascular risk reasoning breaks down for me is the step from the group result to the individual case. That step is almost never argued for.
Hepatic impairment and the absence of data Replied, post #15 · Clinical › Special populations · 18 Aug 2025 · 9 likes Adding the measurement that post #12 says would settle it. Before the thread moves on from hepatic impairment — what is the sample size behind the claim? I am not being…
Documentation that appears only after payment Replied, post #7 · Sourcing › Red flags · 18 Aug 2025 · 26 likes Since documentation keeps coming up, it should probably be a maintained page rather than a recurring thread. I am happy to draft it if someone with more direct…
A ten-fold dose error caught before injection — one year on Replied, post #136 · Devices › Syringes & needles · 5 Aug 2025 · 20 likes Thank you for the correction. I would rather find out here than later.
Validating a method you did not develop Started this topic · Analytics › Method validation · 1 Aug 2025 · 5 likes On the subject in the title: Validating a method you did not develop Working notes rather than a conclusion. What changes if the standard account of validating a method…
Journal club: indirect comparison between two programmes, defended and attacked — one… Replied, post #24 · Evidence › Journal club · 27 Jul 2025 · 4 likes I read post #22 twice before replying, because I had assumed the opposite. Critical appraisal template: (1) What did the trial set out to estimate? (2) Could the design…
Counter-ion content and its effect on measured mass Replied, post #103 · Analytics › Mass spectrometry · 26 Jul 2025 · 10 likes Deamidation adds approximately one dalton and produces a species that frequently elutes very close to the parent. It is the hardest common impurity to see…
Coming back to: Nausea profile of amylin analogues compared with GLP-1 agonists Replied, post #8 · Compounds › Cagrilintide & amylin analogues · 5 Jul 2025 · 0 likes Helpful, and easy to find again, which is half of what a good reply is.
A report I filed that turned out to be wrong, and the correction Replied, post #121 · Sourcing › Vendor reports · 25 Jun 2025 · 0 likes The maintainers will ask for missing fields rather than rejecting a report. Filling them in afterwards is normal and nobody minds. Adding a source would improve this…
[2026 update] Splitting an overlong document into two Replied, post #11 · Documentation › Wiki requests · 20 Jun 2025 · 7 likes This follows post #8 rather than contradicting it. Correction requests: if you spot an error in a maintained page, note it here with the specific correction. The…
Reading an MS report that only gives you a single number Replied, post #109 · Analytics › Mass spectrometry · 16 Jun 2025 · 2 likes Positional isomers and epimers are mass-identical. Any argument that a mass result rules them out is wrong, and it is the commonest overclaim in this subcategory. It is…
Reading a trial's population section before its results — does this still hold? Replied, post #127 · Evidence › Trials · 21 May 2025 · 10 likes Registration before enrolment, with the primary endpoint declared, is what makes outcome switching detectable. Checking the registry against the paper takes five…
Telehealth prescribing models in the US Replied, post #97 · Regional › North America · 11 May 2025 · 0 likes United States: FDA licenses compounds. Prescribing and pharmacy practice are state-regulated. Compounds are prescription-only. Coverage is decided by individual plans,…
Splitting a vial for two laboratories: how to do it without ruining both Replied, post #26 · Sourcing › Independent verification · 25 Apr 2025 · 14 likes Picking up post #23: that is the part I would want checked first. Where two services agree with each other and with the declared figure, that is a genuinely strong…
Why pulsatile secretion matters for interpreting secretagogue claims — a second dataset Replied, post #58 · Compounds › Secretagogues & GH axis · 12 Apr 2025 · 0 likes Ipamorelin is usually described as selective in that it produces less of an effect on cortisol and prolactin than earlier compounds in the family. Selective is a…
Validating a calculator against hand arithmetic — what changed since Started this topic · Data & Tools › Calculators · 1 Apr 2025 · 1 like Posting this under the heading it deserves: Validating a calculator against hand arithmetic — what changed since Everything below is what sits behind that. What changes…
One lot is one lot: when a report becomes a pattern — the long version Replied, post #110 · Sourcing › Vendor reports · 18 Mar 2025 · 2 likes A difference inside method repeatability is not a disagreement. Saying so in your own report prevents somebody else reading it as one. I keep a log of this specifically…
Airline travel with a temperature-sensitive injectable — what changed since Replied, post #8 · Devices › Cold chain · 13 Mar 2025 · 14 likes The documentation on Airline travel is better than this thread and I say that as someone who has posted in the thread.
Journal club: SUSTAIN 6 and its retinopathy signal — does this still hold? Replied, post #53 · Evidence › Journal club · 8 Mar 2025 · 5 likes Post #52 is right about the mechanism and I think understates the practical bit. On SUSTAIN 6, the part that usually goes wrong is that the question is asked as though…
Revisiting: Bug report: the reconstitution calculator and a rounding edge case Replied, post #113 · Data & Tools › Calculators · 3 Mar 2025 · 0 likes Thank you — that answers what I came here to find out.
What we do not know about retatrutide, listed explicitly Replied, post #114 · Compounds › Retatrutide · 27 Feb 2025 · 17 likes Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from…
Coming back to: Reading a meta-analysis you disagree with, fairly Replied, post #30 · Evidence › Meta-analyses · 7 Feb 2025 · 1 like A note on how Reading a meta-analysis gets discussed rather than on Reading a meta-analysis itself: the confident posts get the replies and the careful ones get…
Research-use-only status: what it means legally and practically — a second dataset Replied, post #81 · Compounds › Other compounds · 4 Feb 2025 · 4 likes Adding a null result on Research-use-only status. I looked, carefully, and found nothing, and null results deserve posting precisely because they never are.
Journal club: SURMOUNT-1, read without the press release Replied, post #48 · Evidence › Journal club · 23 Jan 2025 · 1 like Narrowing post #47, because the general version has more than one answer. A note on scope: what I am saying about SURMOUNT-1 applies to the case in the first post and I…
Follow-up: Tirzepatide's shorter half-life and its one practical consequence Replied, post #137 · Compounds › Tirzepatide · 8 Jan 2025 · 8 likes Where I part company with post #135, and it is a narrow parting. Storage and stability: published data on licensed tirzepatide formulations exists and is worth reading…
What the published dose-response for semaglutide actually looks like above 2.4 mg — a… Replied, post #20 · Compounds › Semaglutide · 8 Jan 2025 · 11 likes The version of published dose-response for semaglutide that circulates here is a simplification of a simplification. It is not wrong, but it has lost the conditions…
Converting between mg/mL and units per dose, both directions Replied, post #142 · Practice › Reconstitution · 23 Dec 2024 · 8 likes Post #141 is right about the mechanism and I think understates the practical bit. Preservative effectiveness is tested against a defined microbial challenge under…
Body image changing more slowly than the body Replied, post #77 · Wellbeing › Mental health · 19 Dec 2024 · 14 likes Where a member is finding this hard, the useful reply is usually a question rather than an answer, and this subcategory does that well.
Persistent vomiting and the threshold for seeking help — one year on Replied, post #8 · Safety › Adverse events · 18 Dec 2024 · 1 like Rechallenge is the observation that would be most informative and is also the one that carries the most risk. That decision is not a forum decision. I would want the…
Second pass at: A field-by-field walk through a certificate of analysis Replied, post #149 · Analytics › COA interpretation · 12 Dec 2024 · 5 likes What I would check first on field-by-field walk through a certificate is whether the thing being measured moved or whether the way of measuring it moved. Those look…
SURPASS-2 and the comparator dose question that will not go away Replied, post #75 · Compounds › Tirzepatide · 9 Dec 2024 · 31 likes SURMOUNT-4's randomised withdrawal design is the strongest available evidence about what happens on stopping. It says nothing about a lower maintenance dose, because…
Type 1 diabetes: off-label use and the evidence gap — what changed since Replied, post #21 · Clinical › Special populations · 21 Nov 2024 · 6 likes Answering the question post #19 raises rather than the one it answers. Type 1 diabetes is worth one more sentence than it usually gets, and the sentence is the one…
EMA product information as a primary source — does this still hold? Replied, post #77 · Regional › European Union · 17 Nov 2024 · 8 likes EMA is the regulator with national implementation. Licensed incretin analogues are prescription-only across the EU, with some variation in specific approvals by member…
Tirzepatide storage and stability: what is published versus what is assumed — does this… Replied, post #9 · Compounds › Tirzepatide · 15 Nov 2024 · 5 likes Storage and stability: published data on licensed tirzepatide formulations exists and is worth reading directly rather than through summarised claims. Reconstituted…
Time to steady state after a dose increase Replied, post #107 · Pharmacology › Pharmacokinetics · 5 Nov 2024 · 14 likes Post #103 put the caveat in the right place and I want to underline it. A pharmacokinetic model fitted to trial data describes the population studied. Applying it to…
Hypertension improvement and when medication needs revisiting — a second dataset Replied, post #54 · Clinical › Comorbidities · 18 Oct 2024 · 0 likes Taking post #53 at face value and following it one step further. Filing a mild objection to the consensus on Hypertension improvement. Mild because I might be wrong; an…
Reporting a discrepancy without making an allegation Replied, post #73 · Sourcing › Vendor reports · 14 Sep 2024 · 7 likes Dosing and purity: a vial that is 99% pure might contain 80% of its label claim if the other mass is water, counter-ion, and excipient. Purity and content are…
Guidelines revision: what changed and why Replied, post #143 · Meta › Announcements · 29 Jul 2024 · 3 likes I would call the community position on guidelines revision likely rather than established, and I would be comfortable defending that hedge.